Staff Pick /Features
ISAL 2017: Developments in acute leukemias
The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
1 year
The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma
Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…
Multiple Myeloma
1 year
TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients
Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…
Chronic Myeloid Leukemia
1 year
ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma
As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…
Multiple Myeloma
Promoted Post
2 years
Positive Phase III results for plitidepsin
Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…
Multiple Myeloma
2 years
